Recursion’s First AI Clinical Proof Links Pipeline Progress With Valuation Gap

Recursion Pharmaceuticals (NasdaqGS:RXRX) reports its first AI enabled clinical proof of concept in familial adenomatous polyposis. The company advances five clinical programs, signaling broader use ...
Hosted on MSN

Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock

Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier this ...
Forbes

Recursion Announces New Generative AI Platform To Speed Up Drug Discovery

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...
GEN

Drugs, Dollars, and Data: Recursion Eyes Cost Savings from AI Drug Discovery

Announcing an artificial intelligence (AI) drug discovery partnership with Nvidia earlier this month, Recursion co-founder and CEO Chris Gibson, PhD, spoke as much about dollars as he did about drugs ...